Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology firm focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company has market cap of $1.41 billion. The companyÂ’s research and development focuses on four disease targets: Hepatitis C virus , Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). It has a 41.93 P/E ratio. The Company’s lead product is paritaprevir, a protease inhibitor designed for use against HCV.

Energizer Holdings, Inc. (ENR) formed double bottom with $48.61 target or 9.00% below today’s $53.42 share price. Energizer Holdings, Inc. (ENR) has $3.19B valuation. The stock increased 0.94% or $0.5 during the last trading session, reaching $53.42. About 1.03 million shares traded or 13.15% up from the average. Energizer Holdings, Inc. (NYSE:ENR) has risen 21.70% since February 10, 2017 and is uptrending. It has outperformed by 5.00% the S&P500.

Among 10 analysts covering Edgewell Personal Care Company (ENR) (NYSE:ENR), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Edgewell Personal Care Company (ENR) has $70.0 highest and $37 lowest target. $57.20’s average target is 7.08% above currents $53.42 stock price. Edgewell Personal Care Company (ENR) had 48 analyst reports since July 29, 2015 according to SRatingsIntel. KeyBanc Capital Markets maintained the stock with “Buy” rating in Tuesday, January 16 report. The firm has “Hold” rating by Jefferies given on Monday, July 24. The stock has “Buy” rating by RBC Capital Markets on Friday, July 14. RBC Capital Markets maintained it with “Buy” rating and $6000 target in Thursday, June 8 report. The stock has “Neutral” rating by UBS on Thursday, August 4. The stock has “Hold” rating by Jefferies on Thursday, August 4. Jefferies maintained the shares of ENR in report on Wednesday, August 2 with “Hold” rating. As per Friday, January 8, the company rating was downgraded by Jefferies. The company was maintained on Thursday, August 4 by Citigroup. RBC Capital Markets maintained it with “Outperform” rating and $52 target in Friday, August 7 report.

Analysts await Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to report earnings on February, 14. They expect $0.04 earnings per share, up 115.38% or $0.30 from last year’s $-0.26 per share. ENTA’s profit will be $766,004 for 458.88 P/E if the $0.04 EPS becomes a reality. After $1.86 actual earnings per share reported by Enanta Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -97.85% negative EPS growth.